[1]
Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015; 4: 27066.
[2]
Hong BS, Cho JH, Kim H, et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 2009; 10: 556.
[3]
Mirzaei H, Sahebkar A, Jaafari MR, et al. Diagnostic and therapeutic potential of exosomes in cancer: The beginning of a new tale? J Cell Physiol 2017; 232(12): 3251-60.
[4]
Saeedi Borujeni MJ, Esfandiary E, Taheripak G, et al. Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome. J Cell Biochem 2018; 119(2): 1257-72.
[5]
Tavakolizadeh J, Roshanaei K, Salmaninejad A, et al. MicroRNAs and exosomes in depression: Potential diagnostic biomarkers. J Cell Biochem 2018; 119(5): 3783-97.
[6]
Chaput N, Théry C. Exosomes: Immune properties and potential clinical implementations. Semin Immunopathol 2011; 33: 419-40.
[7]
Barres C, Blanc L, Bette-Bobillo P, et al. Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake by macrophages. Blood 2011; 115: 696-705.
[8]
Nazarenko I, Rana S, Baumann A, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 2010; 70: 1668-78.
[9]
Mathivanan S, Ji H, Simpson RJ. Exosomes: Extracellular organelles important in intercellular communication. J Proteomics 2010; 73: 1907-20.
[10]
Calzolari A, Raggi C, Deaglio S, et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 2006; 119: 4486-98.
[11]
Clayton A, Turkes A, Dewitt S, et al. Adhesion and signaling by B cell-derived exosomes: The role of integrins. FASEB J 2004; 18: 977-99.
[12]
Aggarwal SK, Wagner RW, McAllister PK, et al. Cell-surface-associated nucleic acid in tumorigenic cells made visible with platinum-pyrimidine complexes by electron microscopy. Proc Natl Acad Sci USA 1975; 72: 928-32.
[13]
Rieber M, Bacalao J. An “external” RNA removable from mammalian cells by mild proteolysis. Proc Natl Acad Sci USA 1974; 71: 4960-4.
[14]
Skvortsova TE, Rykova EYu, Tamkovich SN, et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006; 94: 1492-5.
[15]
Tamkovich SN, Bryzgunova OE, Rykova EYu, et al. Circulating nucleic acids in blood of healthy male and female donors. Clin Chem 2005; 51: 1317-9.
[16]
Lekchnov EA, Zaporozhchenko IA, Morozkin ES, et al. Protocol for miRNA isolation from biofluids. Anal Biochem 2016; 499: 78-84.
[17]
van Schooneveld E, Wouters MC, Van der Auwera I, et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res 2012; 14: R34.
[18]
Hu Z, Dong J, Wang LE, et al. Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis 2012; 33: 828-34.
[19]
Rousseau N, Pige R, Cohen R, et al. What is the acceptable hemolysis index for the measurements of plasma potassium, LDH and AST? Ann Biol Clin (Paris) 2016; 74: 323-8.
[20]
Novitsky VV, Ryazantseva NV, Stepovaya YeA, et al. Molecular erythrocyte membrane disorders in pathology of different genesis are the typical reaction of the organism: Contours of the problem. Bull Sib Med 2006; 5: 62-9.
[21]
Beliaev ND, Budker VG, Gorokhova OE, et al. Mg2+-dependent interaction of DNA with eukaryotic cells. Mol Biol (Mosk) 1988; 22: 1667-72.
[22]
Akers JC, Ramakrishnan V, Nolan JP, et al. Comparative analysis of technologies for quantifying extracellular vesicles (EVs) in clinical cerebrospinal fluids (CSF). PLoS One 2016; 11: e0149866.
[23]
van der Pol E, Coumans FA, Grootemaat AE, et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 2014; 12: 1182-92.
[24]
Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2013; 2: 20360.
[25]
Yuana Y, Levels J, Grootemaat A, et al. Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation. J Extracell Vesicles 2014; 3: e23262.
[26]
Gornall AG, Bardawill CJ, David MN. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949; 177: 751-66.
[27]
Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 2014; 3: 26913.
[28]
Lässer C, Alikhani VS, Ekström K, et al. Human saliva, plasma and breast milk exosomes contain RNA: Uptake by macrophages. J Transl Med 2011; 14: 9.
[29]
King JB, von Furstenberg RJ, Smith BJ, et al. CD24 can be used to isolate Lgr5+ putative colonic epithelial stem cells in mice. Am J Physiol Gastrointest Liver Physiol 2012; 303: G443-52.
[30]
Royo F, Zuñiga-Garcia P, Torrano V, et al. Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer. Oncotarget 2016; 7: 6835-46.
[31]
Barger JF, Rahman MA, Jackson D, et al. Extracellular miRNAs as biomarkers in cancer Food Chem Toxicol 2016; 98(Pt A): 66-72.
[32]
Tomasetti M, Lee W, Santarelli L, et al. Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp Mol Med 2017; 49: e285.
[33]
Jafari SH, Saadatpour Z, Salmaninejad A, et al. Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol 2018; 233(7): 5200-13.
[34]
Liu Y, Li H, Feng J, et al. Lin28 induces epithelial-to-mesenchymal transition and stemness via downregulation of let-7a in breast cancer cells. PLoS One 2013; 8: e83083.
[35]
Wu Q, Wang C, Lu Z, et al. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta 2012; 413: 1058-65.
[36]
Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol 2013; 9: 53-9.
[37]
Hannafon BN, Sebastiani P, de las Morenas A, et al. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 2011; 13: R24.
[38]
Bryzgunova OE, Zaripov MM, Skvortsova TE, et al. Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients. PLoS One 2016; 11: e0157566.
[39]
Tamkovich SN, Tutanov OS, Laktionov PP. Exosomes: generation, structure, transport, biological activity, and diagnostic application. Biochem Moscow Suppl A 2016; 10: 163-73.
[40]
Nazimek K, Bryniarski K, Santocki M, et al. Exosomes as mediators of intercellular communication: clinical implications. Pol Arch Med Wewn 2015; 125: 370-80.
[41]
Steinbichler TB, Dudás J, Riechelmann H, et al. The role of exosomes in cancer metastasis. Semin Cancer Biol 2017; 44: 170-81.
[42]
Danesh A, Inglis HC, Jackman RP, et al. Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro. Blood 2014; 123: 687-96.
[43]
Minciacchi VR, Freeman MR, Di Vizio D. Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev Biol 2015; 40: 41-51.
[44]
Hong CS, Funk S, Muller L, et al. Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. J Extracell Vesicles 2016; 5: e29289.
[45]
Nakai W, Yoshida T, Diez D, et al. A novel affinity-based method for the isolation of highly purified extracellular vesicles. Sci Rep 2016; 6: e33935.
[46]
Oliveira-Rodriguez M, Lopez-Cobo S, Reyburn HT, et al. Development of a rapid lateral flow immunoassay test for detection of exosomes previously enriched from cell culture medium and body fluids. J Extracell Vesicles 2016; 5: e31803.
[47]
Saadatpour L, Fadaee E, Fadaei S, et al. Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther 2016; 23(12): 415-8.
[48]
Thind A, Wilson C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. J Extracell Vesicles 2016; 5: 31292.
[49]
Wang Z, Chen J-O, Liu J-I, et al. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med 2016; 14: 297.
[50]
Tomasetti M, Lee W, Santarelli L, et al. Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp Mol Med 2017; 49: e285.
[51]
Helland A, Anglesio MS, George J, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011; 6: e18064.
[52]
Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 2014; 9: e92921.
[53]
Tian Y, Xue Y, Ruan G, et al. Interaction of serum microRNAs and serum folate with the susceptibility to pancreatic cancer. Pancreas 2015; 44: 23-30.
[54]
Shivapurkar N, Weiner LM, Marshall JL, et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One 2014; 9: e84686.
[55]
Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
[56]
Chow TF, Youssef YM, Lianidou E, et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010; 43: 150-8.
[57]
Elyakim E, Sitbon E, Faerman A, et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res 2010; 70: 8077-87.
[58]
Zhang Y, Zhang D, Wang F, et al. Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Sci Rep 2015; 5: 17942.
[59]
Yongchun Z, Linwei T, Xicai W, et al. MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett 2014; 347: 65-74.
[60]
Guo J, Wang M, Liu X. MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res 2015; 34: 91.
[61]
Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010; 15: 673-82.
[62]
Flavin RJ, Smyth PC, Laios A, et al. Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol 2009; 22: 197-205.
38
6